CytoMed Therapeutics Limited Ordinary Shares company info

What does CytoMed Therapeutics Limited Ordinary Shares do?
CytoMed Therapeutics (NASDAQ:GDTC) focuses on the innovation and development of advanced therapies in the biotechnological arena, aiming to push the boundaries in treating various diseases. The company engages in the research, development, and potentially the commercialization of novel drug therapies, which encompasses a wide range of medical conditions. Their projects typically involve cutting-edge technologies and approaches, such as targeted drug delivery systems, gene therapy, and immunotherapy, aiming to address unmet medical needs and improve patient outcomes. With a commitment to excellence and innovation, CytoMed Therapeutics strives to lead in the development of transformative treatments that can significantly impact healthcare and patient wellbeing. Their objective is not only to pioneer in their field but also to ensure that their discoveries and developments are accessible to those in need, thus contributing positively to global healthcare challenges.
CytoMed Therapeutics Limited Ordinary Shares company media
Company Snapshot

Is CytoMed Therapeutics Limited Ordinary Shares a public or private company?

key
Ownership
Public

How many people does CytoMed Therapeutics Limited Ordinary Shares employ?

people
Employees
28

What sector is CytoMed Therapeutics Limited Ordinary Shares in?

pie chart
Sector
Health Care

Where is the head office for CytoMed Therapeutics Limited Ordinary Shares?

location pin
Head Office
Singapore, Singapore

What year was CytoMed Therapeutics Limited Ordinary Shares founded?

founded flag
Year Founded
2018
What does CytoMed Therapeutics Limited Ordinary Shares specialise in?
/Biopharmaceutical Development /Cancer Therapies /Autoimmune Treatments /Drug Discovery /Clinical Trials /Research Projects

What are the products and/or services of CytoMed Therapeutics Limited Ordinary Shares?

Overview of CytoMed Therapeutics Limited Ordinary Shares offerings
Development of innovative immunotherapies for cancer and autoimmune diseases, leveraging unique cell engineering technologies.
Production of CAR-T cell therapies aimed at providing personalized treatments for various cancer types.
Manufacture of monoclonal antibodies designed to target specific cancer cells, enhancing the precision of cancer treatment.
Research and development of biosimilars to expand access to high-quality, cost-effective treatment options for chronic diseases.
Provision of cell therapy services, offering expertise in cell processing, expansion, and cryopreservation for medical institutions.
Creation of diagnostic tools that assist in the early detection and monitoring of cancer and autoimmune diseases.

Who is in the executive team of CytoMed Therapeutics Limited Ordinary Shares?

CytoMed Therapeutics Limited Ordinary Shares leadership team
  • Mr. Chee Kong  Choo
    Mr. Chee Kong Choo
    Executive Chairman
  • Dr. Wee Kiat  Tan Ph.D.
    Dr. Wee Kiat Tan Ph.D.
    COO & Director
  • Dr. Jieming  Zeng
    Dr. Jieming Zeng
    Chief Scientific & Medical Officer and Director
  • Dr. Tien Wee  Luk
    Dr. Tien Wee Luk
    Chief Clinical Officer & Director
  • Ms. Yvonne  Goh
    Ms. Yvonne Goh
    Chief Financial Officer
  • Ms. Yoong Ying  Tan
    Ms. Yoong Ying Tan
    Chief Corporate Officer